However, the potential benefits of SGLT2 inhibitors have not been specifically evaluated in the ADPKD population, because major clinical trials in CKD without diabetes have excluded individuals with this condition.3 This evidence concerns the gene SLC5A2 and autosomal dominant polycystic kidney disease.